drugset / Trial / NCT02994394
A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
To assess the bioequivalence of OPC-41061 OD tablets and OPC-41061 conventional tablets at 15 and 30 mg in healthy adult male subjects.
Timeline
- Start
- 2017-01-06
- Primary completion
- 2017-02-28
- Completion
- 2017-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolvaptan | Small molecule | 15 mg | — |
| Subject | Tolvaptan | Small molecule | 30 mg | — |
Indications
No indication recorded.